Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norditropine SimpleXx is a liquid formulation of somatropin, a recombinant human growth hormone (rhGH), designed for use in specialized delivery pens. Developed and manufactured by Novo Nordisk, it contains a 191-amino acid polypeptide chain that is identical to the growth hormone naturally produced by the human pituitary gland. Somatropin acts as a potent agonist at the Growth Hormone Receptor (GHR), initiating signaling cascades (primarily the JAK2/STAT5 pathway) that stimulate the production of Insulin-like Growth Factor 1 (IGF-1). This process promotes longitudinal bone growth, protein synthesis, and metabolic regulation. It is indicated for children with growth failure due to growth hormone deficiency, Turner syndrome, Noonan syndrome, chronic renal insufficiency, and for children born small for gestational age (SGA) who fail to show catch-up growth. It is also utilized for replacement therapy in adults with confirmed growth hormone deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Norditropine SimpleXx.